World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
79
Citations
18115
World Ranking
17749
National Ranking
8857

Overview

Sharyn D. Baker is affiliated with The Ohio State University in the United States and has a substantial publication record primarily within the fields of Medicine and Biochemistry, Genetics and Molecular Biology. Their research covers significant subfields including Hematology, Molecular Biology, Oncology, Genetics, and Pharmacology.

Their recent papers address a variety of topics and have been published in well-regarded venues:

  • "A new genomic framework to categorize pediatric acute myeloid leukemia" (2024), Nature Genetics
  • "Targeting OCT3 attenuates doxorubicin-induced cardiac injury" (2021), Proceedings of the National Academy of Sciences
  • "A kinome-wide screen identifies a CDKL5-SOX9 regulatory axis in epithelial cell death and kidney injury" (2020), Nature Communications
  • "Boosting the oral bioavailability of anticancer drugs through intentional drug-drug interactions" (2021), Basic & Clinical Pharmacology & Toxicology
  • "Role of OATP1B1 and OATP1B3 in Drug-Drug Interactions Mediated by Tyrosine Kinase Inhibitors" (2020), Pharmaceutics

Baker frequently collaborates with other researchers, with the most common coauthors including:

  • Alex Sparreboom (44 joint publications)
  • Eric D. Eisenmann (34 joint publications)
  • Daelynn R. Buelow (29 joint publications)
  • Shelley Orwick (20 joint publications)
  • Yan Jin (16 joint publications)

Baker's publications often appear in select journals noted for research in pharmacology, hematology, and molecular biology:

  • Journal of Pharmacology and Experimental Therapeutics (10 publications)
  • Blood (10 publications)
  • Journal of Chromatography B (5 publications)
  • The FASEB Journal (5 publications)
  • Pharmaceutics (4 publications)

Their main research topics concentrate on Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, Drug Transport and Resistance Mechanisms, Chronic Lymphocytic Leukemia Research, Epigenetics and DNA Methylation, Cancer Genomics and Diagnostics, and Protein Degradation and Inhibitors. These subjects align with the breadth of their published work and indicate a consistent focus on hematologic cancers, drug mechanisms, and molecular biology of disease.

Best Publications

  • The genomic landscape of hypodiploid acute lymphoblastic leukemia

    Linda Holmfeldt;Lei Wei;Ernesto Diaz-Flores;Michael Walsh

  • CREBBP mutations in relapsed acute lymphoblastic leukaemia

    Charles G. Mullighan;Jinghui Zhang;Lawryn H. Kasper;Stephanie Lerach

  • Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy.

    Clet Niyikiza;Sharyn D Baker;David E Seitz;Jackie M Walling

  • Differential Metabolism of Gefitinib and Erlotinib by Human Cytochrome P450 Enzymes

    Jing Li;Ming Zhao;Ping He;Manuel Hidalgo

  • Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001

    Sharyn D. Baker;Jaap Verweij;Eric K. Rowinsky;Ross C. Donehower

  • Irinotecan Pathway Genotype Analysis to Predict Pharmacokinetics

    Ron H. J. Mathijssen;Sharon Marsh;Mats O. Karlsson;Rujia Xie

  • An Epidermal Growth Factor Receptor Intron 1 Polymorphism Mediates Response to Epidermal Growth Factor Receptor Inhibitors

    Maria L. Amador;Darin Oppenheimer;Sofia Perea;Anirban Maitra

  • A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies.

    Jill Gilbert;Sharyn D. Baker;M. Katherine Bowling;Louise Grochow

  • Absorption, Metabolism, and Excretion of 14C-Temozolomide following Oral Administration to Patients with Advanced Cancer

    Sharyn D. Baker;Sharyn D. Baker;Mark Wirth;Paul Statkevich;Pascale Reidenberg

  • Pharmacogenetics of ABCG2 and Adverse Reactions to Gefitinib

    George Cusatis;Vanesa Gregorc;Jing Li;Anna Spreafico

  • Interaction of Imatinib with Human Organic Ion Carriers

    Shuiying Hu;Ryan M. Franke;Kelly K. Filipski;Kelly K. Filipski;Chaoxin Hu

  • Tumor Targeting by Covalent Conjugation of a Natural Fatty Acid to Paclitaxel

    Matthews O. Bradley;Nigel L. Webb;Forrest H. Anthony;Prabu Devanesan

  • Clinical pharmacokinetics of docetaxel : recent developments.

    Sharyn D. Baker;Alex Sparreboom;Jaap Verweij

  • A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.

    David A. Rinaldi;John G. Kuhn;Howard A. Burris;F. Andrew Dorr

  • Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients.

    Jing Li;George Cusatis;Julie Brahmer;Alex Sparreboom

  • The Influence of Protein Binding upon Tissue Fluid Levels of Six β-Lactam Antibiotics

    R. Wise;A. P. Gillett;B. Cadge;S. R. Durham

  • Crenolanib is active against models of drug-resistant FLT3-ITD−positive acute myeloid leukemia

    Eric I. Zimmerman;David C. Turner;Jassada Buaboonnam;Shuiying Hu

  • Pharmacogenetic pathway analysis of docetaxel elimination.

    SD Baker;J Verweij;GA Cusatis;RH van Schaik

  • Evaluation of Alternate Size Descriptors for Dose Calculation of Anticancer Drugs in the Obese

    Alex Sparreboom;Antonio C. Wolff;Ron H.J. Mathijssen;Etienne Chatelut

  • Interaction of the Multikinase Inhibitors Sorafenib and Sunitinib with Solute Carriers and ATP-Binding Cassette Transporters

    Shuiying Hu;Zhaoyuan Chen;Ryan Franke;Shelley Orwick

Frequent Co-Authors

Alex Sparreboom
Alex Sparreboom The Ohio State University
Jeffrey E. Rubnitz
Jeffrey E. Rubnitz St. Jude Children's Research Hospital
Ross C. Donehower
Ross C. Donehower Johns Hopkins University
Jaap Verweij
Jaap Verweij Erasmus University Rotterdam
Michael A. Carducci
Michael A. Carducci Johns Hopkins University
Manuel Hidalgo
Manuel Hidalgo Cornell University
Raul C. Ribeiro
Raul C. Ribeiro St. Jude Children's Research Hospital
Stanley Pounds
Stanley Pounds St. Jude Children's Research Hospital
Wells A. Messersmith
Wells A. Messersmith University of Colorado Boulder
Eric K. Rowinsky
Eric K. Rowinsky Eli Lilly (United States)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering alternative or complementary pathways to studying Medicine in the USA? There are a variety of accredited online nursing and healthcare degrees that provide fast and flexible options for advancing your medical career.

For those seeking a terminal nursing degree, the quickest dnp program options can dramatically reduce study time while enhancing clinical leadership skills. If research and lengthy dissertations are a concern, many students opt for online dnp programs without dissertation requirements, streamlining the path to a doctorate in nursing.

Entry-level healthcare professionals can explore fast track lpn programs to quickly start working in the medical field. Meanwhile, registered nurses interested in mental health can pursue fast track mental health nursing pathways to specialize faster than traditional routes.

These online programs offer greater flexibility, allowing you to balance work and study while accessing in-demand healthcare roles. Whether you’re just starting or looking to specialize, these alternative pathways can help you achieve your career goals efficiently.

Best Scientists Citing Sharyn D. Baker

Trending Scientists

Recently Published Articles